Celcuity Inc.
$120.09
▼
-0.27%
2026-04-21 05:58:01
www.celcuity.com
NCM: CELC
Explore Celcuity Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.8 B
Current Price
$120.09
52W High / Low
$127.34 / $9.5
Stock P/E
—
Book Value
$2.08
Dividend Yield
—
ROCE
-40.76%
ROE
-1.64%
Face Value
—
EPS
$-3.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
155
Beta
0.42
Debt / Equity
320.13
Current Ratio
10.55
Quick Ratio
10.55
Forward P/E
-106.49
Price / Sales
—
Enterprise Value
$5.54 B
EV / EBITDA
-32.22
EV / Revenue
—
Rating
Strong Buy
Target Price
$128.6
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 2. | Arcturus Therapeutics Holdings Inc. | $8.9 | — | $251.54 M | — | -32.48% | -28.92% | $24.17 / $5.85 | $7.53 |
| 3. | Nuvalent, Inc. | $107.99 | — | $8.48 B | — | -31.35% | -36.7% | $113.02 / $63.55 | $15.96 |
| 4. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 5. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 6. | Forte Biosciences, Inc. | $34.43 | — | $674.68 M | — | -113.91% | -1.22% | $35.8 / $4.9 | $4.71 |
| 7. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -49.2 M | -42.85 M | -44.01 M | -36.13 M | -36.43 M |
| Net Profit | -50.97 M | -43.8 M | -45.27 M | -37 M | -36.65 M |
| EPS in Rs | -1.05 | -0.91 | -0.94 | -0.77 | -0.76 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -172.19 M | -113.27 M | -66.23 M | -39.39 M |
| Net Profit | -177.04 M | -111.78 M | -63.78 M | -40.37 M |
| EPS in Rs | -3.66 | -2.31 | -1.32 | -0.84 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 466.56 M | 245.12 M | 191.22 M | 175.7 M |
| Total Liabilities | 366 M | 129.5 M | 51.45 M | 41.93 M |
| Equity | 100.56 M | 115.62 M | 139.77 M | 133.77 M |
| Current Assets | 465.66 M | 244.57 M | 190.59 M | 175.19 M |
| Current Liabilities | 44.15 M | 31.72 M | 14.19 M | 6.88 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -153.28 M | -83.47 M | -53.81 M | -36.01 M |
| Investing CF | -64.08 M | -63.07 M | -5.01 M | -144.03 M |
| Financing CF | 360.55 M | 138.39 M | 64.91 M | 120.33 M |
| Free CF | -153.53 M | -83.72 M | -53.91 M | -36.17 M |
| Capex | -0.25 M | -0.25 M | -0.1 M | -0.16 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -75.26% | -57.99% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.